Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease …

OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney
Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular …

Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …

Background In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney
Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose …

Aims Dapagliflozin is a selective inhibitor of sodium glucose co‐transporter 2 (SGLT2). This
study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with …

Background Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney
disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified …

Background Dapagliflozin's antihyperglycemic effects are mediated by inhibition of renal
sodium-glucose cotransporter-2; therefore, renal safety of dapagliflozin was assessed …

Abstract Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic
Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the …

Objectives The purpose of this paper was to investigate the effects of dapagliflozin in chronic
kidney disease (CKD) patients, with and without heart failure (HF). Background Patients with …

Aims Mortality rates from chronic kidney disease (CKD) have increased in the last decade. In
this pre-specified analysis of the DAPA-CKD trial, we determined the effects of dapagliflozin …